Jessica Hernández-Pineda

Ms. Jessica Hernández-Pineda

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
EREdson Jiovany Ramírez-Nava
Edson Jiovany Ramírez-Nava
DODaniel Ortega
Daniel Ortega
HSHugo Serrano-Posada
Hugo Serrano-Posada
AGAbigail González-Valdez
Abigail González-Valdez
AVAmerica Vanoye-carlo
America Vanoye-carlo
SGSaul Gomez-Manzo
Saul Gomez-Manzo
Glucose-6-phosphate dehydrogenase (G6PD) is a key regulatory enzyme that plays a crucial role in the regulation of cellular energy and redox balance. Mutations in the gene encoding G6PD cause the most common enzymopathy that drives hereditary nonspherocytic hemolytic anemia. To gain insights into the effects of mutations in G6PD enzyme efficiency, we have investigated the biochemical, kinetic, and structural changes of three clinical G6PD variants, the single mutations G6PD A+ (Asn126AspD) and G6PD Nefza (Leu323Pro), and the double mutant G6PD A− (Asn126Asp + Leu323Pro). The mutants showed lower residual activity (≤50% of WT G6PD) and displayed important kinetic changes. Although all Class III mutants were located in different regions of the three-dimensional structure of the enzyme and were not close to the active site, these mutants had a deleterious effect over catalytic activity and structural stability. The results indicated that the G6PD Nefza mutation was mainly responsible for the functional and structural alterations observed in the double mutant G6PD A−. Moreover, our study suggests that the G6PD Nefza and G6PD A− mutations affect enzyme functions in a similar fashion to those reported for Class I mutations.

19 January 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ARAlicia Ramírez-Ramírez
Alicia Ramírez-Ramírez
ESElías Sánchez-Serrano
Elías Sánchez-Serrano
GLGiselle Loaiza-Flores
Giselle Loaiza-Flores
NPNoemí Plazola-Camacho
Noemí Plazola-Camacho
RRRosa Georgina Rodríguez-Delgado
Rosa Georgina Rodríguez-Delgado
JHJessica Hernández-Pineda
Jessica Hernández-Pineda
The primary strategy to avoid mother-to-child transmission of human immunodeficiency virus (HIV) through breastfeeding is administration of highly active antiretroviral therapy (HAART) to HIV-positive pregnant women. Because significant changes in the pharmacokinetics of antiretroviral (ARV) drugs occur during pregnancy, quantifying HAART and the viral load in breast milk in this population is essential. Here, we developed an analytical assay for the simultaneous quantification of four ARV drugs in breast milk using ultra-performance liquid chromatography coupled to tandem mass spectrometry. We validated this method following Mexican and international guidelines. ARV drugs. We extracted the ARV drugs from 200 μL samples of breast milk and detected these drugs in a triple quadrupole mass spectrometer with positive electrospray ionization. The validated concentration ranges (ng/mL) for zidovudine, lamivudine, lopinavir, and ritonavir were 12.5–750, 50–2500, 100–5000 and 5 to 250, respectively. Additionally, the absolute recovery percentages (and matrix effects) were 91.4 (8.39), 88.78 (28.75), 91.38 (11.77) and 89.78 (12.37), respectively. We determined that ARV drugs are stable for 24 h at 8°C and 24°C for 15 days at –80°C. This methodology had the capacity for simultaneous detection; separation; and accurate, precise quantification of ARV drugs in human breast milk samples according to Mexican standard laws and United States Food and Drug Administration guidelines.

24 August 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
Nadia RiveroNadia Rivero
Nadia Rivero
EZEmmanuel Alejandro Zepeda-Arzate
Emmanuel Alejandro Zepeda-Arzate
SCSelma Karime Castillo-Vazquez
Selma Karime Castillo-Vazquez
PPPatrick Fleischmann de la Parra
Patrick Fleischmann de la Parra
JHJessica Hernández-Pineda
Jessica Hernández-Pineda
CVCarlos Verjan
Carlos Verjan
Aging is the result of the accumulation of a wide variety of molecular and cellular damages over time, meaning that “the more damage we accumulate, the higher the possibility to develop age-related diseases”. Therefore, to reduce the incidence of such diseases and improve human health, it becomes important to find ways to combat such damage. In this sense, geroprotectors have been suggested as molecules that could slow down or prevent age-related diseases. On the other hand, nutraceuticals are another set of compounds that align with the need to prevent diseases and promote health since they are biologically active molecules (occurring naturally in food) that, apart from having a nutritional role, have preventive properties, such as antioxidant, anti-inflammatory and antitumoral, just to mention a few. Therefore, in the present review using the specialized databases Scopus and PubMed we collected information from articles published from 2010 to 2023 in order to describe the role of nutraceuticals during the aging process and, given their role in targeting the hallmarks of aging, we suggest that they are potential geroprotectors that could be consumed as part of our regular diet or administered additionally as nutritional supplements.

15 November 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
MDMauricio Domínguez-Castro
Mauricio Domínguez-Castro
ADArely Domínguez-Galicia
Arely Domínguez-Galicia
OPOscar Pérez-Pérez
Oscar Pérez-Pérez
JHJessica Hernández-Pineda
Jessica Hernández-Pineda
IMIsmael Mancilla-Herrera
Ismael Mancilla-Herrera
JRJose Romo-Yañez
Jose Romo-Yañez

15 September 2022 in Nutrition and Cancer
Verified
Journal Article
Closed access
EGEstela Godínez-Martínez
Estela Godínez-Martínez
RSRené Santillán
René Santillán
RSReyna Sámano
Reyna Sámano
GCGabriela Chico-Barba
Gabriela Chico-Barba
MTMari Cruz Tolentino
Mari Cruz Tolentino
JHJessica Hernández-Pineda
Jessica Hernández-Pineda
The Estrogen Metabolites (2-hydroxyestrogens: 16α-hydroxyestrone) Urine Ratio (EMUR) has been negatively associated with breast cancer; Mexican women have a lower EMUR than other populations. We evaluated the effectiveness of 3,3′-diindolylmethane (DIM) supplementation on increasing EMUR in premenopausal women. A randomized, double-blind clinical trial (NCT02525159 at ClinicalTrial.gov) was carried out on 60 women with an EMUR below 0.9. Patients were assigned randomly to receive a placebo or 75 mg of DIM a day (administered as 300 mg of DIM-BR®) for 30 day. Urine samples were obtained at baseline, at 30 day of supplementation, and 30 day after finishing supplementation. A Mann-Whitney U test was used to compare the EMUR; an ANOVA was used to analyze differences in body composition. EMUR was analyzed using ESTRAMET™ kits. While DIM-treated subjects did not increase their EMUR at 30 day of supplementation (p > 0.05), there was a non-significant positive trend 30 day once supplementation ended (p = 0.06). The DIM group saw a more significant decrease in body fat percentage than the placebo group (p = 0.04). In premenopausal Mexican women, 75 mg of the daily DIM supplement was ineffective in increasing EMUR; further studies are needed to evaluate the effective dosage, time frames, and effect on body fat.

19 June 2025 in Metabolites
Verified
Journal Article
Open access
PDF file
SCSelma Karime Castillo-Vazquez
Selma Karime Castillo-Vazquez
BPBerenice Palacios-Gonzalez
Berenice Palacios-Gonzalez
Marcela Vela-AmievaMarcela Vela-Amieva
Marcela Vela-Amieva
IGIsabel Ibarra González
Isabel Ibarra González
RMRicardo Morales
Ricardo Morales
Nadia RiveroNadia Rivero
Nadia Rivero
Background/Objectives: Insomnia has been widely associated with cognitive impairment (CI). However, the relationship between the two entities (insomnia and CI) is poorly understood. In this context, adults with insomnia show metabolic changes, including alterations in the catabolism of branched-chain amino acids, glycerophospholipids, and glutathione and glutamate biosynthesis. Nevertheless, aging itself induces metabolic changes that may be amplified by chronic diseases that compromise the health of the elderly. Therefore, in the present study we aim to characterise metabolomic profiles of insomnia and CI alone in order to address a significant gap in current research regarding the pathways through which insomnia may lead to CI in older persons. Methods: In this study we perform a targeted metabolomics analysis (UPLC-MS) on 80 serum samples from the Cohort of Obesity, Sarcopenia, and Frailty of Older Mexican Adults (COSFOMA); these samples were classified into four groups (control, insomnia, CI, and insomnia + CI). Results: Our results show that insomnia increases the concentration of acylcarnitines (C10, C8, C14, C12:1, C18:1 and C18) as compared to CI group, while older persons with CI show a decrease the concentration of the acylcarnitines C16, C10 and C8. Finally, individuals with both conditions (insomnia + CI) show that only the concentration of the acylcarnitine C16 decreases compared to controls. Conclusions: Taken together, our results shed light on the relevance of insomnia on lipid metabolism in older persons.